Skip to main content
Clinical Trials/NCT06057480
NCT06057480CompletedNot Applicable

A Prospective, Multicenter, Single-arm Study Examining the Assisted Programming Module (APM) in the Evoke Spinal Cord Stimulation (SCS) System to Program Patients With Chronic Pain of the Trunk and/or Limbs

Saluda Medical Pty Ltd4 sites in 1 country30 target enrollmentStarted: September 26, 2023Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Sponsor
Enrollment
30
Locations
4
Primary Endpoint
Succsessful Use of APM

Study Overview

Brief Summary

Study to evaluate the use of the Assisted Programming Module (APM) in the Evoke Spinal Cord Stimulation (SCS) System to program patients with chronic pain of the trunk and/or limbs.

Study Design

Study Type
Interventional
Allocation
Na
Intervention Model
Single Group
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Subject has or is planning to undergo a temporary trial with Evoke System within the FDA approved indication.
  • •Subject is willing and capable of giving informed consent and able to comply with study-related requirements.

Exclusion Criteria

  • •There are no exclusion criteria.

Arms & Interventions

APM

Experimental

Investigational programming software module, the Assisted Programming Module (APM)

Intervention: Evoke Spinal Cord Stimulation System (Device)

Outcomes

Primary Outcomes

Succsessful Use of APM

Time Frame: All timepoints through study completion, on average 3-months post-implant procedure.

Of all APM uses, the workflow was able to generate a closed-loop program 134 (96%) times.

Change in Evoked Compound Action Potentials (ECAPs) measured in µV by the Evoke SCS System

Time Frame: end of trial period; 1 month and 3 months post-implant

Change in Evoked Compound Action Potentials (ECAPs) measured in µV by the Evoke SCS System

Change in programming parameters (e.g., stimulation frequency [Hz], pulse width [µs], amplitude [mA]) measured by the Evoke SCS System

Time Frame: end of trial period; 1 month and 3 months post-implant

Change in programming parameters (e.g., stimulation frequency \[Hz\], pulse width \[µs\], amplitude \[mA\]) measured by the Evoke SCS System

Secondary Outcomes

  • Time to Generate APM Program When Closed-loop Program Achieved(All uses through study completion in which APM was initiated)

Investigators

Sponsor
Saluda Medical Pty Ltd
Sponsor Class
Industry
Responsible Party
Sponsor

Study Sites (4)

Loading locations...

Similar Trials